查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465961

下一代癌症診斷市場：按技術、癌症類型、應用、功能分類 - 2024-2030 年全球預測

Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

下一代癌症診斷市場規模預計到2023年為97.7億美元，到2024年達到120.2億美元，預計到2030年將達到443.6億美元，複合年成長率為24.12%。

調查方法包括用於檢測和表徵癌症的工具、技術和方法的最新技術進步。該市場專注於與傳統診斷方法相比提高準確性、靈敏度和特異性的技術創新。其中包括用於早期檢測、預後預測和癌症治療監測的基因組學、表觀基因、表觀基因組學、成像技術和生物資訊學工具。下一代癌症診斷的擴展是由多種因素推動的，包括全球癌症發病率的增加、基因組測序技術的進步以及對個人化醫療的日益重視。此外，政府的措施和癌症研究資助也對市場成長做出了重大貢獻。將人工智慧和機器學習融入診斷也為提高癌症檢測和預後的準確性提供了機會。儘管市場開拓廣闊，但下一代癌症診斷市場仍面臨一些限制和挑戰。先進診斷技術的高成本可能會限制這些工具的使用，特別是在低收入和中等收入國家。此外，癌症生物學的複雜性和腫瘤類型的多樣性對開發普遍有效的診斷解決方案提出了挑戰。監管障礙和強大的臨床檢驗的需求也減緩了市場創新的步伐。然而，液態切片、循環腫瘤 DNA (ctDNA) 分析和非侵入性成像技術等最新發展為早期癌症檢測和監測開闢了新途徑。這些進步代表著市場成長的巨大機會。此外，次世代定序儀（NGS）在癌症診斷中的應用不斷發展，為發現新的生物標記和治療標靶提供了潛力。

主要市場統計
基準年[2023] 97.7億美元
預測年份 [2024] 120.2億美元
預測年份 [2030] 443.6億美元
複合年成長率（%） 24.12%

技術 對識別與癌症相關突變的分子診斷的需求增加

簇狀規則間隔短回文重複診斷技術為癌症診斷提供了一種革命性的方法，利用基因編輯功能來準確檢測癌症突變。該技術提供了快速、準確且經濟高效的診斷潛力，從根本上改變了癌症的識別和治療方式。 DNA 微陣列可以在一次實驗中同時分析數千個 DNA 序列。該技術用於癌症診斷，以識別不同癌症類型特異性的基因突變和表達，從而促進個人化治療計劃。晶片實驗室將多個測試步驟整合到一個晶片中，為癌症診斷提供了緊湊而高效的解決方案。當與 RT-PCR（一種測量基因表現的方法）結合時，它成為在分子層面上檢測和量化癌症標記的強大工具。分子診斷分析 DNA 和 RNA 的鹼基序列以識別與癌症相關的突變。該領域強調遺傳分析在癌症早期檢測、分類和管理中的重要性，並提供量身定做的治療方法。 NGS 透過序列測定百萬個 DNA 片段來提供全面的基因組分析。該技術可以深入了解導致癌症的基因突變，從而能夠確定標靶治療並改善患者的治療結果。蛋白質微陣列大規模分析蛋白質表現和相互作用。在癌症診斷中，它用於研究癌症引起的蛋白質變化，有助於發現用於早期檢測和治療策略的新生物標記。定量聚合酵素鏈鎖反應(qPCR) 是一種擴增和定量目標 DNA 分子的技術。多重分析可同時測量多種分析物，增強了 qPCR 在癌症診斷中的能力，讓單次測試檢測與癌症相關的多個基因。

應用範例 在治療監測中部署診斷工具以追蹤癌症治療的有效性

癌症篩檢是對抗癌症的第一道防線，利用下一代診斷技術來識別沒有明顯症狀的人是否患有癌症。該領域專注於癌症的早期檢測，旨在在治療最有可能成功的階段診斷疾病。先進的影像技術、分子診斷和生物標記評估是用於提高癌症篩檢有效性的工具。伴同性診斷是專門的測試，旨在識別最有可能從標靶治療中受益的患者。該領域透過確定預測患者對標靶治療的反應的特定遺傳和分子標記的存在，在個人化醫療中發揮重要作用。在下一代癌症診斷的背景下，基因組分析通常用於針對個別癌症制定治療策略。下一代癌症診斷的預後工具用於預測診斷患者的癌症病程和結果。該領域有助於評估疾病侵襲性、復發風險和整體存活率預測。透過利用先進的基因組和蛋白質組分析，預後診斷藥物支持有關治療性介入的需求和強度的明智決策，最終指導患者管理計劃。下一代癌症診斷的風險分析著重於根據遺傳、環境和生活方式因素評估個體患癌症的風險。該領域使用各種基因測試和生物標記評估方法來識別患有某些癌症的高風險個體，從而有可能採取有針對性的預防措施和更頻繁、​​更詳細的監測計劃。治療監測使用下一代診斷工具來追蹤癌症治療的有效性並監測疾病進展或復發徵兆。此應用領域對於即時調整治療計劃、管理副作用和改善患者治療效果至關重要。透過使用循環腫瘤 DNA (ctDNA)、成像技術和其他生物標記物，治療監測可以詳細了解腫瘤對治療的反應，並促進個人化治療調整。

區域洞察

美國，特別是美國，透過對研發的大量投資正在取得快速進展。重點主要是精準醫學和非侵入性診斷技術，例如用於檢測循環腫瘤 DNA 的液態切片。歐洲、中東和非洲地區在下一代癌症診斷的採用和開發方面呈現出多樣化的景象。歐洲在該地區處於領先地位，在強大的醫療保健系統和公共衛生政策的支持下，一些國家支持將基因序列測定和生物標記分析整合到標準癌症治療中。中東，特別是以色列和阿拉伯聯合大公國等國家，正迅速崛起為包括癌症診斷在內的醫療技術創新中心。非洲面臨更多挑戰，包括資源限制，但透過國際夥伴關係和改善癌症護理基礎設施和可近性的努力正在取得進展。由於癌症發病率上升、醫療保健支出增加以及早期癌症檢測意識的提高，亞太地區下一代癌症診斷市場正在經歷顯著成長。日本、韓國、中國和澳洲處於領先地位，在醫療保健技術和研究方面投入大量資金。特別是在中國，利用人工智慧的診斷工具等技術正在迅速發展，並表現出很高的採用率。除其他福利外，該地區受益於快速發展的生物技術新興企業以及全球和本地公司之間旨在根據當地特點客製化癌症診斷的戰略聯盟。

FPNV定位矩陣

FPNV 定位矩陣對於評估下一代癌症診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對下一代癌症診斷市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.下一代癌症診斷市場的市場規模與預測為何？

2.在下一代癌症診斷市場的預測期內，需要考慮投資的產品、細分市場、應用和領域有哪些？

3.下一代癌症診斷市場的技術趨勢和法規結構是什麼？

4.下一代癌症診斷市場主要廠商的市場佔有率為何？

5.進入下一代癌症診斷藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症患者數量不斷增加，提高了對有效診斷的需求。
      • 擴大微流體控晶片在癌症治療的應用
      • 政府癌症篩檢舉措
    • 抑制因素
      • 診斷投資高且標準化不足
    • 機會
      • 個人化/先進基因組醫學的普及
      • 下一代癌症診斷的技術進步
    • 任務
      • NGC 診斷相關的局限性和風險
  • 市場區隔分析
    • 技術：對分子診斷的需求增加，以識別與癌症相關的突變
    • 應用：在治療監測中部署診斷工具來追蹤癌症治療效果
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章下一代癌症診斷市場：依技術分類

  • 叢集規則間隔短回文重複的診斷
  • DNA微陣列
  • 實驗室晶片和逆轉錄 PCR
  • 分子診斷
  • 次世代定序
  • 蛋白質微陣列
  • qPCR 和多重檢測

第7章按癌症類型分類的下一代癌症診斷藥物市場

  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 腎癌
  • 肺癌
  • 胰臟癌
  • 攝護腺癌
  • 甲狀腺癌
  • 子宮癌

第8章下一代癌症診斷市場：按應用分類

  • 癌症篩檢
  • 伴同性診斷
  • 預言
  • 風險分析
  • 治療監測

第 9 章下一代癌症診斷市場：按功能分類

  • 生物標記開發
  • CTC分析
  • 表觀遺傳分析
  • 遺傳分析
  • 蛋白質體分析

第10章 北美和南美下一代癌症診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區下一代癌症診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的下一代癌症診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Genialis 開發基於生物標記的癌症診斷模型
    • Thermo Fisher Scientific 與 Arsenal Biosciences 合作支持自體 T 細胞療法的臨床生產
    • 輝瑞430億美元收購Seagen並將重心轉向腫瘤學
    • Ibex 和 Albano Laboratories 簽署癌症診斷人工智慧的多年、多組織擴展協議
    • 斯旺西生物科技新興企業籌集了 150 萬英鎊用於人工智慧結腸癌血液檢測
    • 醫療保健精準醫學透過下一代篩檢加速精準腫瘤學並支持新的癌症診斷

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-AD36CD898567

[187 Pages Report] The Next-Generation Cancer Diagnostics Market size was estimated at USD 9.77 billion in 2023 and expected to reach USD 12.02 billion in 2024, at a CAGR 24.12% to reach USD 44.36 billion by 2030.

The next-generation cancer diagnostics market encompasses the latest technological advancements in the tools, techniques, and methodologies utilized to detect and characterize cancers. This market focuses on innovations that offer enhanced accuracy, sensitivity, and specificity compared to traditional diagnostic methods. It includes genomic, proteomic, and epigenomic analysis, imaging techniques, and bioinformatics tools for early detection, prognosis, and cancer treatment monitoring. Several factors drive the expansion of next-generation cancer diagnostics, including the increasing global prevalence of cancer, advancements in genomic sequencing technologies, and the growing emphasis on personalized medicine. Furthermore, government initiatives and funding for cancer research contribute significantly to market growth. Integrating artificial intelligence and machine learning in diagnostics also presents opportunities for enhanced precision in cancer detection and prognosis. Despite the promising development, the next-generation cancer diagnostics market faces several limitations and challenges. High costs associated with advanced diagnostic technologies can limit access to these tools, particularly in low- and middle-income countries. Moreover, the complexity of cancer biology and the variability in tumor types pose challenges in developing universally effective diagnostic solutions. Regulatory hurdles and the need for robust clinical validation also slow down the market's pace of innovation. However, recent developments in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and non-invasive imaging techniques have opened new avenues for early cancer detection and monitoring. These advancements present significant opportunities for market growth. Moreover, the application of next-generation sequencing (NGS) in cancer diagnostics continues to evolve, offering the potential to discover novel biomarkers and therapeutic targets.

KEY MARKET STATISTICS
Base Year [2023] USD 9.77 billion
Estimated Year [2024] USD 12.02 billion
Forecast Year [2030] USD 44.36 billion
CAGR (%) 24.12%

Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer

Clustered regularly interspaced short palindromic repeats diagnostics technology presents a revolutionary approach to cancer diagnostics, leveraging its gene editing capabilities to detect cancer mutations precisely. This technique offers the potential for rapid, accurate, and cost-effective diagnostics, fundamentally changing how cancers are identified and treated. DNA microarrays enable the simultaneous analysis of thousands of DNA sequences in a single experiment. This technology is used in cancer diagnostics to identify gene mutations and expressions specific to different cancer types, facilitating personalized treatment plans. Lab-on-a-chip integrates multiple laboratory processes into a single chip, offering a compact and efficient solution for cancer diagnostics. Combined with RT-PCR, a method that measures gene expression, it provides a powerful tool for detecting and quantifying cancer markers at the molecular level. Molecular diagnostics involves analyzing DNA or RNA sequences to identify cancer-related mutations. This segment emphasizes the importance of genetic analysis in the early detection, classification, and management of cancer, offering a tailored approach to therapy. NGS offers comprehensive genomic profiling by sequencing millions of DNA fragments in parallel. This technology provides deep insights into the genetic mutations that cause cancer, allowing for the identification of targeted therapies and better outcomes for patients. Protein microarrays analyze the expression and interaction of proteins on a large scale. In cancer diagnostics, they are used to study protein changes caused by cancer, aiding in discovering new biomarkers for early detection and treatment strategies. Quantitative Polymerase Chain Reaction (qPCR) is a technique that amplifies and quantifies a targeted DNA molecule. Multiplexing, simultaneously measuring multiple analytes, enhances qPCR's capability in cancer diagnostics, allowing for detecting multiple genes associated with cancer in a single test.

Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments

Cancer screening represents the first line of defense in combating cancer, utilizing next-generation diagnostic technologies to identify the presence of cancer in individuals showing no apparent symptoms. This segment focuses on early cancer detection, aiming to diagnose diseases at a stage where they are more likely to be treated successfully. Advanced imaging technologies, molecular diagnostics, and biomarker assessment are tools used to enhance cancer screening efficacy. Companion diagnostics are specialized tests designed to identify patients most likely to benefit from a targeted therapy. This segment plays a critical role in personalized medicine by determining the presence of specific genetic or molecular markers that predict how well a patient will respond to targeted therapy options. In the context of next-generation cancer diagnostics, this often involves using genomic profiling to tailor treatment strategies to the individual's cancer. Prognostic tools in next-generation cancer diagnostics are employed to predict cancer's likely course and outcome in diagnosed patients. This segment helps in assessing disease aggression, the risk of recurrence, and overall survival expectations. By leveraging advanced genomic and proteomic analysis, prognostic diagnostics aid in making informed decisions regarding the necessity and intensity of therapeutic interventions, ultimately guiding patient management plans. Risk analysis in next-generation cancer diagnostics focuses on assessing an individual's risk of developing cancer based on genetic, environmental, and lifestyle factors. This segment utilizes various genetic testing and biomarker evaluation methods to identify individuals at higher risk for developing specific cancers, potentially leading to targeted preventive measures or more frequent and detailed surveillance programs. Therapeutic monitoring involves using next-generation diagnostic tools to track the effectiveness of cancer treatments and monitor for signs of disease progression or recurrence. This application segment is crucial for adjusting treatment plans in real time, managing side effects, and improving patient outcomes. Through the employment of circulating tumor DNA (ctDNA), imaging technologies, and other biomarkers, therapeutic monitoring provides detailed insights into the tumor's response to treatment and facilitates personalized treatment adjustments.

Regional Insights

In the Americas, particularly the United States, next-generation cancer diagnostics are experiencing rapid advancements, largely driven by significant investments in research and development. The focus is largely on precision medicine and non-invasive diagnostic techniques, such as liquid biopsies that detect circulating tumor DNA. The EMEA region shows a diverse landscape in adopting and developing next-generation cancer diagnostics. Europe leads within the region, with several countries incorporating genomic sequencing and biomarker analysis into standard cancer care, supported by strong healthcare systems and public healthcare policies. The Middle East, particularly countries such as Israel and the United Arab Emirates, are rapidly emerging as innovative hubs for medical technology, including cancer diagnostics. Africa faces more challenges, including resource limitations, but progress is being made through international partnerships and initiatives to improve cancer care infrastructure and accessibility. The Asia-Pacific region is witnessing significant growth in the next-generation cancer diagnostics market, driven by rising cancer prevalence, growing healthcare expenditure, and a surge in awareness about early cancer detection. Japan, South Korea, China, and Australia are at the forefront, investing heavily in healthcare technology and research. China, in particular, has seen rapid advancements and high adoption rates of technologies such as AI-driven diagnostic tools. Additionally, the region benefits from several fast-growing biotech startups and strategic collaborations between global and local firms aiming to tailor cancer diagnostics to regional specificities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMerieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
    • DNA Microarrays
    • Lab-on-a-Chip & Reverse Transcriptase-PCR
    • Molecular Diagnostics
    • Next Generation Sequencing
    • Protein Microarrays
    • qPCR & Multiplexing
  • Cancer Type
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Thyroid Cancer
    • Uterine Cancer
  • Application
    • Cancer Screening
    • Companion Diagnostics
    • Prognostics
    • Risk Analysis
    • Therapeutic Monitoring
  • Function
    • Biomarker Development
    • CTC Analysis
    • Epigenetic Analysis
    • Genetic Analysis
    • Proteomic Analysis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Next-Generation Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
      • 5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
      • 5.1.1.3. Government Initiatives Towards Cancer Screening
    • 5.1.2. Restraints
      • 5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
      • 5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
    • 5.2.2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Next-Generation Cancer Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
  • 6.3. DNA Microarrays
  • 6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
  • 6.5. Molecular Diagnostics
  • 6.6. Next Generation Sequencing
  • 6.7. Protein Microarrays
  • 6.8. qPCR & Multiplexing

7. Next-Generation Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Bladder Cancer
  • 7.3. Breast Cancer
  • 7.4. Cervical Cancer
  • 7.5. Colorectal Cancer
  • 7.6. Kidney Cancer
  • 7.7. Lung Cancer
  • 7.8. Pancreatic Cancer
  • 7.9. Prostate Cancer
  • 7.10. Thyroid Cancer
  • 7.11. Uterine Cancer

8. Next-Generation Cancer Diagnostics Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Screening
  • 8.3. Companion Diagnostics
  • 8.4. Prognostics
  • 8.5. Risk Analysis
  • 8.6. Therapeutic Monitoring

9. Next-Generation Cancer Diagnostics Market, by Function

  • 9.1. Introduction
  • 9.2. Biomarker Development
  • 9.3. CTC Analysis
  • 9.4. Epigenetic Analysis
  • 9.5. Genetic Analysis
  • 9.6. Proteomic Analysis

10. Americas Next-Generation Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Next-Generation Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
    • 13.3.2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
    • 13.3.3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
    • 13.3.4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
    • 13.3.5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
    • 13.3.6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 187. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 196. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 203. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 210. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 211. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 226. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 237. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 238. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 239. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 244. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 245. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 246. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 247. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 252. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 253. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 260. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 261. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 268. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 269. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 276. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 277. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 284. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 285. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 286. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 287. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 292. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS